首页> 外文期刊>Eye and Vision >PACK-CXL: Corneal cross-linking in infectious keratitis
【24h】

PACK-CXL: Corneal cross-linking in infectious keratitis

机译:PACK-CXL:角膜交联在感染性角膜炎中

获取原文
       

摘要

BackgroundCorneal cross-linking (CXL) using ultraviolet light-A (UV-A) and riboflavin is a technique developed in the 1990’s to treat corneal ectatic disorders such as keratoconus. It soon became the new gold standard in multiple countries around the world to halt the progression of this disorder, with good long-term outcomes in keratometry reading and visual acuity. The original Dresden treatment protocol was also later on used to stabilize iatrogenic corneal ectasia appearing after laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK). CXL efficiently strengthened the cornea but was also shown to kill most of the keratocytes within the corneal stroma, later on repopulated by those cells. ReviewUltraviolet-light has long been known for its microbicidal effect, and thus CXL postulated to be able to sterilize the cornea from infectious pathogens. This cytotoxic effect led to the first clinical trials using CXL to treat advanced infectious melting corneal keratitis. Patients treated with this technique showed, in the majority of cases, a stabilization of the melting process and were able to avoid emergent à chaud keratoplasty. Following those primary favorable results, CXL was used to treat beginning bacterial keratitis as a first-line treatment without any adjunctive antibiotics with positive results for most patients. In order to distinguish the use of CXL for infectious keratitis treatment from its use for corneal ectatic disorders, a new term was proposed at the 9th CXL congress in Dublin to rename its use in infections as photoactivated chromophore for infectious keratitis -corneal collagen cross-linking (PACK-CXL). ConclusionPACK-CXL is now more frequently used to treat infections from various infectious origins. The original Dresden protocol is still used for this purpose. Careful modifications of this protocol could improve the efficiency of this technique in specific clinical situations regarding certain types of pathogens.
机译:背景技术使用紫外线A(UV-A)和核黄素的角膜交联(CXL)是1990年代开发的一种技术,用于治疗角膜扩张疾病,例如圆锥角膜。不久,它成为制止这种疾病发展的新的金本位制,在角膜测定法阅读和视敏度方面具有良好的长期效果。最初的德累斯顿治疗方案后来也用于稳定在激光辅助原位角膜磨镶术(LASIK)和光折射角膜切除术(PRK)后出现的医源性角膜扩张。 CXL有效地增强了角膜,但也显示出可以杀死角膜基质内的大多数角质形成细胞,随后又被这些细胞所填充。综述紫外线因其杀菌作用而广为人知,因此CXL被认为能够对传染病原体的角膜进行灭菌。这种细胞毒性作用导致了首次使用CXL治疗晚期感染性融化角膜角膜炎的临床试验。用这种技术治疗的患者在大多数情况下显示出融化过程的稳定,并且能够避免出现急速角膜角膜成形术。在取得这些最初的良好效果之后,CXL被用作一线治疗,不使用任何辅助抗生素,而对大多数患者则是阳性结果,是一线治疗。为了将CXL用于治疗感染性角膜炎与用于角膜直肠疾病的区别开来,在都柏林第九届CXL大会上提出了一个新术语,将其在感染中的应用重命名为光活化发色团,用于感染性角膜炎-角膜胶原交联(PACK-CXL)。结论PACK-CXL现在更常用于治疗来自各种感染源的感染。原始的德累斯顿协议仍用于此目的。仔细修改此协议可以在某些类型病原体的特定临床情况下提高该技术的效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号